These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35177981)

  • 1. Sodium-Glucose Co-Transporter 2 Inhibitors Use Improves the Satisfaction With Anti-diabetic Agent Treatment: A Questionnaire-based Propensity Score-matched Study.
    Shi FH; Yue J; Jiang YH; Yang ML; Gu ZC; Ma J; Li H
    Front Pharmacol; 2021; 12():787704. PubMed ID: 35177981
    [No Abstract]   [Full Text] [Related]  

  • 2. Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus.
    Kinduryte Schorling O; Clark D; Zwiener I; Kaspers S; Lee J; Iliev H
    Adv Ther; 2020 Aug; 37(8):3463-3484. PubMed ID: 32372290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
    Birkeland KI; Jørgensen ME; Carstensen B; Persson F; Gulseth HL; Thuresson M; Fenici P; Nathanson D; Nyström T; Eriksson JW; Bodegård J; Norhammar A
    Lancet Diabetes Endocrinol; 2017 Sep; 5(9):709-717. PubMed ID: 28781064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Liu J; Li L; Li S; Wang Y; Qin X; Deng K; Liu Y; Zou K; Sun X
    Diabetes Obes Metab; 2020 Sep; 22(9):1619-1627. PubMed ID: 32364674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study.
    Cesaro A; Gragnano F; Paolisso P; Bergamaschi L; Gallinoro E; Sardu C; Mileva N; Foà A; Armillotta M; Sansonetti A; Amicone S; Impellizzeri A; Esposito G; Morici N; Oreglia JA; Casella G; Mauro C; Vassilev D; Galie N; Santulli G; Pizzi C; Barbato E; Calabrò P; Marfella R
    Front Cardiovasc Med; 2022; 9():1012220. PubMed ID: 36237914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practical considerations for the use of sodium-glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes.
    Lam KS; Chow CC; Tan KC; Ma RC; Kong AP; Tong PC; Tsang MW; Chan TM; Tang SC; Lee KK; So WY; Tomlinson B
    Curr Med Res Opin; 2016 Jun; 32(6):1097-108. PubMed ID: 26933918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium-glucose co-transporter-2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: A nationwide population-based cohort study.
    Kim YG; Jeon JY; Han SJ; Kim DJ; Lee KW; Kim HJ
    Diabetes Obes Metab; 2018 Aug; 20(8):1852-1858. PubMed ID: 29569427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heart failure hospitalization risk associated with use of two classes of oral antidiabetic medications: an observational, real-world analysis.
    Gautam S; Agiro A; Barron J; Power T; Weisman H; White J
    Cardiovasc Diabetol; 2017 Jul; 16(1):93. PubMed ID: 28756774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co-transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases.
    Wang L; Voss EA; Weaver J; Hester L; Yuan Z; DeFalco F; Schuemie MJ; Ryan PB; Sun D; Freedman A; Alba M; Lind J; Meininger G; Berlin JA; Rosenthal N
    Pharmacoepidemiol Drug Saf; 2019 Dec; 28(12):1620-1628. PubMed ID: 31456304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Sodium-Glucose Transporter 2 Inhibitors (SGLT2-I) in Patients With Ischemic Heart Disease (IHD) Treated by Coronary Artery Bypass Grafting
    Sardu C; Massetti M; Testa N; Martino LD; Castellano G; Turriziani F; Sasso FC; Torella M; De Feo M; Santulli G; Paolisso G; Marfella R
    Front Pharmacol; 2021; 12():777083. PubMed ID: 34867407
    [No Abstract]   [Full Text] [Related]  

  • 12. Association of Sodium-Glucose Transport Protein 2 Inhibitor Use for Type 2 Diabetes and Incidence of Gout in Taiwan.
    Chung MC; Hung PH; Hsiao PJ; Wu LY; Chang CH; Wu MJ; Shieh JJ; Chung CJ
    JAMA Netw Open; 2021 Nov; 4(11):e2135353. PubMed ID: 34797368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SGLT2-inhibitors reduce the cardiac autonomic neuropathy dysfunction and vaso-vagal syncope recurrence in patients with type 2 diabetes mellitus: the SCAN study.
    Sardu C; Massimo Massetti M; Rambaldi P; Gatta G; Cappabianca S; Sasso FC; Santamaria M; Volpicelli M; Ducceschi V; Signoriello G; Paolisso G; Marfella R
    Metabolism; 2022 Dec; 137():155243. PubMed ID: 35732222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Adverse Events of High-Dose vs Low-Dose Sodium-Glucose Cotransporter 2 Inhibitors in Type 2 Diabetes: A Meta-Analysis of 51 Randomized Clinical Trials.
    Shi FH; Li H; Yue J; Jiang YH; Gu ZC; Ma J; Lin HW
    J Clin Endocrinol Metab; 2020 Nov; 105(11):. PubMed ID: 32841351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study.
    Heerspink HJL; Karasik A; Thuresson M; Melzer-Cohen C; Chodick G; Khunti K; Wilding JPH; Garcia Rodriguez LA; Cea-Soriano L; Kohsaka S; Nicolucci A; Lucisano G; Lin FJ; Wang CY; Wittbrodt E; Fenici P; Kosiborod M
    Lancet Diabetes Endocrinol; 2020 Jan; 8(1):27-35. PubMed ID: 31862149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute Kidney Injury Events in Patients With Type 2 Diabetes Using SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs: A Retrospective Cohort Study.
    Rampersad C; Kraut E; Whitlock RH; Komenda P; Woo V; Rigatto C; Tangri N
    Am J Kidney Dis; 2020 Oct; 76(4):471-479.e1. PubMed ID: 32464161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effects of sulphonylureas, dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors added to metformin monotherapy: a propensity-score matched cohort study in UK primary care.
    Wilkinson S; Williamson E; Pokrajac A; Fogarty D; Stirnadel-Farrant H; Smeeth L; Douglas IJ; Tomlinson LA
    Diabetes Obes Metab; 2020 May; 22(5):847-856. PubMed ID: 31957254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Sodium-Glucose Co-Transporter 2 Inhibitors on Cardiac Protection.
    Wu VC; Li YR; Wang CY
    Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.
    Rahelić D; Javor E; Lucijanić T; Skelin M
    Ann Med; 2017 Feb; 49(1):51-62. PubMed ID: 27535028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents.
    Vivian EM
    Drugs Context; 2014; 3():212264. PubMed ID: 25598831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.